Go to Top
INVENTOR LOGIN

Details

Project TitleMethod for Treating Infection by Human Papillomavirus
Track Code2011-061
Short Description

Researchers from the University of New Mexico's School of Medicine have demonstrated that EGFR functional inhibitors as well as MAPK inhibitors will cause diminished HPV early gene expression.

Abstract

EGFR pathway inhibitors act as antivirals that prevent viral gene expression and viral genome replication. Inhibiting this feedback by blocking the EGFR pathway with inhibitors can lower viral effects and leading to viral cure or restoration of tumor suppressor p53 and pRb expression such that the cells become destined to die. Many of these EGFR pathways inhibitors are FDA approved for human use, and so could be tested in human tissues and patients.

 
Tagshpv, compounds
 
Posted DateMay 10, 2012 11:01 AM

Researcher

Name
Michelle Ozbun
Julie Bauman

Manager

Name
Jovan Heusser

Background

According to the Centers for Disease Control and Prevention, approximately 20 million Americans are currently infected with human papillomavirus (HPV). Another 6 million people become newly infected each year. HPV is so common that at least 50% of sexually active men and women get it at some point in their lives. 

Research observations suggest HPV oncoprotein expression provides a positive feedback loop for the epidermal growth factor receptor- mitogen-activated protein kinase (EGFR-MAPK) pathway and maintaining cell proliferation.  EGFR plays a crucial role in squamous cell carcinomas (SCCs) and signals through the Ras-MAPK pathway.  EGFR activation of Ras initiates a multistep cascade that leads to the activation of MAPKs including ERK1/2.  Subsequently, ERK1/2 regulates cell transcription and many other transcription factors involved in cell proliferation, survival, and transformation in vitro. Increased MAPK activation has been reported for several human tumors.  Deregulated EGFR-MAPK signaling confers cancer cell survival and enhances resistance to chemotherapy. Therefore, EGFR pathway inhibitors have been developed to act as potential molecular targeting drugs for cancer therapy. 

Technology Description

Researchers from the University of New Mexico’s School of Medicine have demonstrated that EGFR functional inhibitors as well as MAPK inhibitors will cause diminished HPV early gene expression.  EGFR pathway inhibitors act as antivirals that prevent viral gene expression and viral genome replication.  Inhibiting this feedback by blocking the EGFR pathway with inhibitors can lower viral effects and leading to viral cure or restoration of tumor suppressor p53 and pRb expression such that the cells become destined to die.  Many of these EGFR pathways inhibitors are FDA approved for human use, and so could be tested in human tissues and patients.

Advantages/Applications

  • Inhibits viral and bacterial infections and for reducing the extent, severity, frequency, and/or likelihood of viral infections.
  • Lowers viral effects and leads to viral cure or restoration of tumor suppressor p53 and pRb expression such that the cells become destined to die
  • Already-approved therapeutic and prophylactic compounds
  • Inhibition of EGFR sensitizes cells to MAPK pathway inhibitors, and that HPV infected cells will have an additional negative response to the MAPK inhibitors due to intracellular MAPK activation via viral oncoproteins.

INQUIRES

STC has filed intellectual property on this exciting new technology and is currently exploring commercialization options. If you are interested in information about this or other technologies, please contact Arlene Mirabal at amirabal@stc.unm.edu or 505-272-7886.

Files

File Name Description
US 2016/0053026 A1 Published Patent Application None Download